Pharmacological treatment of atrial fibrillation: a review on prevention of recurrences and control of ventricular response.
Atrial fibrillation is the most common sustained arrhythmia, however its treatment remains controversial and problematic. Electrical or pharmacological cardioversion are able to restore sinus rhythm in many patients but maintenance of sinus rhythm requires long term treatment with antiarrrhythmic agents. Today there is major concern regarding the ventricular proarrhythmic effects of antiarrhythmic drugs because they may increase mortality. Even non-cardiac toxicity of these agents must be considered. An alternative strategy based on pharmacological control of ventricular response rate coupled with antithromboembolic prophylaxis can be followed. For rate control digoxin alone has some specific limitations, therefore, use of calcium antagonists (verapamil or diltiazem) or beta-blockers must be considered. At the present time, the relative efficacy and risks of these two alternative strategies in specific patients subgroups remain to be established. Today, non-pharmacological treatments, as atrio-ventricular node ablation are also available. In elderly patients, moreover, advanced age, underlying heart disease, concomitant systemic illnesses and patient compliance to treatments condition our decision making and treatment needs to be individualized. Appropriate knowledge of the advantages, of the limitations and of the costs of every pharmacological or non-pharmacological treatment option is required for deciding in every patient in view of the best risk-benefit and cost-benefit ratio.
Boriani
G
G
Institute of Cardiology, University of Bologna, Policlinico S. Orsola, Via Massarenti 9, 40138 Bologna, Italy.
Biffi
M
M
Branzi
A
A
Magnani
B
B